Cancer-Biomarker-HUNT
- Prosjektnummer
- 46060915
- Ansvarlig person
- Oluf Dimitri Røe
- Institusjon
- NTNU, IKOM
- Prosjektkategori
- Flerårig prosjekt 2014
- Helsekategori
- Cancer
- Forskningsaktivitet
- 4. Detection and Diagnosis
The HUNT lung cancer calculator was published in a Lancet paper, Ebiomedicine, and
Our validated risk prediction model may have a strong impact in future lung cancer screening in Norway and globally. The biomarkers, if validated may increase early diagnosis of lung cancer and mesothelioma and save thousands of lives globally.
[Asbestos and mesothelioma in Denmark 2017: status of a man-made cancer epidemic].
Ugeskr Laeger 2018 Nov 12;180(46).
PMID: 30417819
Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma.
J Clin Oncol 2018 Oct 01;36(28):2863-2871. Epub 2018 aug 16
PMID: 30113886
Mesothelioma diagnosis and prognosis, are we moving beyond histology and performance status towards circulating biomarkers?
J Thorac Dis 2018 Jun;10(Suppl 17):S1956-S1961.
PMID: 30023090
A Validated Clinical Risk Prediction Model for Lung Cancer in Smokers of All Ages and Exposure Types: A HUNT Study.
EBioMedicine 2018 May;31():36-46. Epub 2018 mar 30
PMID: 29678673
The undifferentiated carcinoma that became a melanoma: Re-biopsy of a cancer of an unknown primary site: a case report.
J Med Case Rep 2017 Mar 27;11(1):82. Epub 2017 mar 27
PMID: 28343447
JWA regulates TRAIL-induced apoptosis via MARCH8-mediated DR4 ubiquitination in cisplatin-resistant gastric cancer cells.
Oncogenesis 2017 Jul 03;6(7):e353. Epub 2017 jul 3
PMID: 28671676
The High Cost of New Cancer Therapies-A Challenge of Inequality for All Countries.
JAMA Oncol 2016 Dec 29. Epub 2016 des 29
PMID: 28033441
Excerpts from the 1st international NTNU symposium on current and future clinical biomarkers of cancer: innovation and implementation, June 16th and 17th 2016, Trondheim, Norway.
J Transl Med 2016 Oct 19;14(1):295. Epub 2016 okt 19
PMID: 27756323
JWA loss promotes cell migration and cytoskeletal rearrangement by affecting HER2 expression and identifies a high-risk subgroup of HER2-positive gastric carcinoma patients.
Oncotarget 2016 Jun 14;7(24):36865-36884.
PMID: 27167206
Circulating tumor cells as a prognostic and predictive marker in gastrointestinal stromal tumors: a prospective study.
Oncotarget 2016 Jun 14;7(24):36645-36654.
PMID: 27153560
Prognostic value of perioperative leukocyte count in resectable gastric cancer.
World J Gastroenterol 2016 Mar 07;22(9):2818-27.
PMID: 26973420
Prognostic role of microscopically positive margins for primary gastrointestinal stromal tumors: a systematic review and meta-analysis.
Sci Rep 2016 Feb 19;6():21541. Epub 2016 feb 19
PMID: 26891953
A clinical prognostic scoring system for resectable gastric cancer to predict survival and benefit from paclitaxel- or oxaliplatin-based adjuvant chemotherapy.
Drug Des Devel Ther 2016;10():241-58. Epub 2016 feb 24
PMID: 26966350
Asbestos textile production linked to malignant peritoneal and pleural mesothelioma in women: Analysis of 28 cases in Southeast China.
Am J Ind Med 2015 Oct;58(10):1040-9. Epub 2015 jul 6
PMID: 26147229
The established and future biomarkers of malignant pleural mesothelioma.
Cancer Treat Rev 2015 Jun;41(6):486-95. Epub 2015 mai 8
PMID: 25979846
Activity of pemetrexed-based regimen as first-line chemotherapy for advanced non-small cell lung cancer with asymptomatic inoperable brain metastasis: a retrospective study.
J Chemother 2015 Aug;27(4):221-6. Epub 2015 mar 3
PMID: 25735792
Malignant pleural mesothelioma: history, controversy and future of a manmade epidemic.
Eur Respir Rev 2015 Mar;24(135):115-31.
PMID: 25726562
JWA reverses cisplatin resistance via the CK2-XRCC1 pathway in human gastric cancer cells.
Cell Death Dis 2014;5():e1551. Epub 2014 des 4
PMID: 25476899
Adrenocortical carcinoma mimicking lung cancer and responding to vinorelbine/carboplatin and pemetrexed/carboplatin.
BMJ Case Rep 2014;2014(). Epub 2014 nov 12
PMID: 25391823
Icotinib is an active treatment of non-small-cell lung cancer: a retrospective study.
PLoS One 2014;9(5):e95897. Epub 2014 mai 16
PMID: 24836053
TXNL1-XRCC1 pathway regulates cisplatin-induced cell death and contributes to resistance in human gastric cancer.
Cell Death Dis 2014;5():e1055. Epub 2014 feb 13
PMID: 24525731
The opposite prognostic significance of nuclear and cytoplasmic p21 expression in resectable gastric cancer patients.
J Gastroenterol 2014 Nov;49(11):1441-52. Epub 2013 okt 15
PMID: 24127074
Effective ultra-low doses of erlotinib in patients with EGFR sensitising mutation.
BMJ Case Rep 2014;2014(). Epub 2014 jul 23
PMID: 25056302
Hidden treasures in "ancient" microarrays: gene-expression portrays biology and potential resistance pathways of major lung cancer subtypes and normal tissue.
Front Oncol 2014;4():251. Epub 2014 sep 29
PMID: 25325012
Metabolomics signatures in serum years before thoracic cancer: The HUNT study
2nd International NTNU Symposium on Clinical Biomarkers of Cancer, Trondheim, Norway, 2018
IMPACT OF CALRETININ IMMUNOHISTOCHEMISTRY AND THE IMIG GUIDELINES IN THE MALIGNANT MESOTHELIOMA DIAGNOSIS
IMIG 2018, 2-5th May, Ottawa, Canada
Asbestos consumtion, Eternit and pleural mesothelioma in Norway and Denmark: Similar populations, different stories.
IMIG 2018, 2-5th May, Ottawa, Canada
CHILDHOOD SCHOOL ATTENDANCE NEAR AN ASBESTOS CEMENT PLANT AND ADULT MESOTHELIOMA RISK
IMIG 2018, 2-5th May, Ottawa, Canada
Asbestos disease research in former Soviet Union and Russia; Literature comparisons with United Kingdom and Japan.
IMIG 2018, 2-5th May, Ottawa, Canada
“Reduced” HUNT Lung Cancer Model for Predicting Lung Cancer in the Prospective Danish Lung Cancer Screening Study - Comparison with the NLST
Journal of Thoracic Oncology, 2018, vol 13, issue 10 Supplement, Page S426
Adjuvant Capecitabine and Oxaliplatin vs. Capecitabine and Paclitaxel in Gastric Cancer Patients after D2 Gastrectomy
Journal of Carcinogenesis & Mutagenesis, 8:306. doi: 10.4172/2157-2518.1000306
Mesothelioma and mesothelin—an underused diagnostic biomarker becoming a treatment target
Shanghai Chest doi: 10.21037/shc.2017.11.07
Malignant pleural mesothelioma- history, controversy, and future of a man-made epidemic.
Springer Verlag, “Asbestos and Mesothelioma” edited by Joseph Testa, Fox Chase Cancer Center, USA. ISBN 978-3-319-53560-9, © 2017
Gender differences in asbestos exposure and disease location in 327 patients with mesothelioma
European Respiratory Journal 2017 50: PA4294; DOI: 10.1183/1393003.congress-2017.PA4294
A Validated Clinical Lung Cancer Risk-Prediction Model for Light-, Heavy- and Ex-Smokers: the HUNT Lung Cancer Model
IASLC 18th World Conference on Lung Cancer, Oct. 2017, Yokohama, Japan (Abstract ID 10328)
Metabolic Biomarkers in Serum for the Early Diagnosis of Lung Cancer: First Results from the Cancer-Biomarkers in HUNT Initiative
IASLC 18th World Conference on Lung Cancer, Oct. 2017, Yokohama, Japan (Abstract ID 9792)
Malignant mesothelioma in 91 Danish women - the environmental asbestos exposure
ASCO, Chicago, USA June 2017, J Clin Oncol (Poster 8560)
Metabolomics signature in serum months to years before thoracic cancer: The HUNT study.
ASCO, Chicago, USA June 2017, J Clin Oncol (Abstr e23059)
Pemetrexed as first or second line in 112 Danish patients. ASCO, Chicago, USA June 2016
J Clin Oncol 34, 2016 (suppl; abstr e20084)
Serum microRNAs/enriched pathways in lung cancer 1-4 years before diagnosis: A pilot study from the HUNT Biobank, Norway
ASCO, Chicago, USA June 2016, J Clin Oncol 34, 2016 (suppl; abstr 11539)
Serum biomarkers in mesothelioma 1-3 years before diagnosis -a pilot study
IMIG Birmingham, UK May 2016
BAP-1 cancer syndrome associated malignancies were not detected among 558 Danish patients with malignant mesothelioma
IMIG, Birmingham, May 2016, UK
Asbestos : Lessons learnt.
Pan European Networks: Science and Technology, 2015
Prognostic value of peri-operative leukocyte count in resectable gastric cancer.
World Journal of Gastroenterology, in press, 2015
Skjulte skatter i “gamle” microarrays - Genprofilering portretterer biologi og resistensmekanismer i lungekreft og normalvev
Best Practice, aug. 2015
Asbestos predisposes to pleural or peritoneal disease: Malignant mesothelioma in a female population in North Denmark
IASLC, sept. 2015, Denver, USA
MicroRNA miR-615-3p and let-7b targets multiple key pathways overexpressed in lung adenocarcinoma
IASLC sept. 2015, Denver, USA
Asbestos textile production linked to malignant mesothelioma in women: Analysis of 28 cases in Southeast China
IMIG, Cape Town, 2014
Overrepresentation of malignant peritoneal mesothelioma among females in a cohort of 296 Danish patients
IMIG, Cape Town, 2014
Mesothelioma in women in the Region of North Jutland, Denmark; Non-Occupational asbestos exposure in more than 50% of the cases.
IMIG, Cape Town, 2014
“Hunting” for lung-cancer / mesothelioma early biomarkers: results of a pilot analysis from the Cancer-Biomarker-HUNT study.
IMIG, Cape Town, 2014
The asbestos industry using world-renowned architects to showcase and increase popularity of asbestos construction materials.
IMIG, Cape Town, 2014
Pathology records of the Aalborg University Hospital reveal 562 cases of Mesothelioma and a 13-fold increase in four decades
IMIG, Cape Town, 2014
Xiaofeng Chen, Oluf D. Røe Postoperative leukopenia is an independent prognostic factor in resectable gastric cancer patients
ASCO, 2014
- Vasiliki Panou Prosjektdeltaker
- Jianwei Zhou Prosjektdeltaker
- Mogens Vyberg Prosjektdeltaker
- Frank Skorpen Prosjektdeltaker
- Tone Frost Bathen Prosjektdeltaker
- Davi de Miranda Fonseca Forsker
- Animesh Sharma Prosjektdeltaker
- Sissel Gyrid Freim Wahl Prosjektdeltaker
- Vincenzo Lagani Prosjektdeltaker
- Maria Markaki Prosjektdeltaker
- Ioannis Tsamardinos Prosjektdeltaker
- Erik Larsson Prosjektdeltaker
- Hans Fredrik Nyvold Kvitvang Prosjektdeltaker
- Olav Toai Duc Nguyen Doktorgradsstipendiat
- Arnulf Langhammer Prosjektdeltaker
- Kristian Hveem Prosjektdeltaker
- Robin Mjelle Postdoktorstipendiat
- Oluf Dimitri Røe Forskningsgruppeleder
- Pål Sætrom Prosjektdeltaker
eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT
Alle henvendelser rettes til Helse Midt-Norge RHF - Samarbeidsorganet og FFU